ERBB2 and breast carcinoma: Of these total estimates, the additional $127 million expected with trastuzumab therapy for her2/neu-positive breast cancer likely reflects a current effect, because this agent is currently funded in all Canadian provinces; the $299 million estimate for bevacizumab represents a potential rather than an actual effect, because funding for bevacizumab is currently limited to colorectal cancer and is supported by only a few Canadian provinces.